Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade

Cancer Biology and Therapy

Volumn 3, Issue 6, 2004, Pages 503-504

  Macpherson, Gordon R ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Cancer; Drug development; Glycolysis; HIF 1; Hif 1 ; Hypoxia; PX 478; VEGF; VHL

Indexed keywords

ANTINEOPLASTIC AGENT; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR 1; PX 478; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; 2 AMINO 3 (4' N,N BIS(2 CHLOROETHYL)AMINO)PHENYLPROPIONIC ACID N OXIDE; 2-AMINO-3-(4'-N,N-BIS(2-CHLOROETHYL)AMINO)PHENYLPROPIONIC ACID N-OXIDE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUSTARD GAS DERIVATIVE; PHENYLPROPIONIC ACID DERIVATIVE; TRANSCRIPTION FACTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER REGRESSION; CELL KILLING; COMPARATIVE STUDY; DRUG TARGETING; GLYCOLYSIS; HUMAN; NONHUMAN; SHORT SURVEY; ANIMAL; DRUG ANTAGONISM; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MUSTARD COMPOUNDS; NEOPLASMS; PHENYLPROPIONATES; TRANSCRIPTION FACTORS;

EID: 21644445092     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.6.961     Document Type: Short Survey

References (15)

1. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol Cancer Ther 2004; 3:233-44.
2. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24:68-72.
3. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem 1999; 274:6519-25.
4. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996; 271:32253-9.
5. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95:7987-92.
6. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
7. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14.
8. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 2001; 18:247-56.
9. Tacchini L, Dansi P, Matteucci E, Desiderio MA. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 2001; 22:1363-71.
10. Tacchini L, Dansi P, Matteucci E, Desiderio MA. Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. Exp Cell Res 2003; 290:391-401.
11. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56:941-3.
12. Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1α-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 1999; 209:254-67.
13. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 2002; 277:29936-44.
14. Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 2003; 3:391-405.
15. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 2002; 417:975-8.